29 completed, 7 unknown, 2 not yet recruiting, 2 recruiting. 12 Phase 2, 11 Not applicable, 11 Phase 3, 5 Phase 1, 2 Phase 4.
Follow Dust Mite Allergy: new trials by email Literature Review of Dust Mite Allergy trials Research Report on Dust Mite Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study) Allergy Testing, Peanut Allergies | Completed | Bühlmann Laboratories AG | 38 | 2026-05-15 | 2026-07-17 | |
| Identification of B Regulatory Cells by Flow Cytometry Venepuncture, Allergen Specific Immunotherapy - Pollen Allergy, Venom Allergy | Recruiting | Hull University Teaching Hospitals NHS Trust | 80 | 2026-01-21 | 2026-09-17 | |
| Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic Rhinitis Multi-species probiotic powder for oral solution. Dietary supplement containing six bacterial strains (Lactobacillus and Bifidobacterium species), Placebo Powder for Oral Solution - Perennial Allergic Rhinitis | Not applicable | Completed | Winclove B.V. | 97 | 2025-09-01 | 2026-09-09 |
| Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab Tezepelumab, Acarizax, Placebo - Severe Asthma, Allergy to House Dust Mites | Phase 3 | Not yet recruiting | University Hospital, Montpellier | 38 | 2025-07-15 | 2025-06-10 |
| Efficacy and Safety of SLIT in Patients With Rhinitis/RC With/Without Mild-moderate Asthma, Due to Dpt and/or Df Allergen Immunotherapy Extract - Rhinitis, Rhinoconjunctivitis | Phase 3 | Recruiting | Inmunotek S.L. | 736 | 2025-04-02 | 2026-01-16 |
| Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte Clustoid® Max Forte - Mite Allergy, Dermatophagoides Farinae Allergy | Completed | Inmunotek S.L. | 140 | 2025-03-31 | 2026-02-23 | |
| Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects Skin Prick Automated Test, Skin Prick Manual Test, Nasal Allergen Challenge - House Dust Mite Allergy, Birch Pollen Allergy | Not applicable | Completed | Hippocreates | 75 | 2024-09-17 | 2025-01-31 |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) PURETHAL Mites 50,000 AUeq/ml, Biological/Vaccine: Placebo - House Dust Mite Allergy, House Dust Mite Rhinitis | Phase 3 | Completed | HAL Allergy | 691 | 2024-09-09 | 2026-08-10 |
| Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract 3,000 MM09, 9,000 MM09, Placebo sublingual - Allergic Rhinitis, Allergic Asthma | Phase 2 / Phase 3 | Not yet recruiting | Inmunotek S.L. | 90 | 2023-11-01 | 2023-10-23 |
| Dupilumab Effects Against Aeroallergen Challenge Dupilumab, House Dust Mites (HDM), Placebo - Asthma, Allergic | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 96 | 2023-03-29 | 2026-08-11 |
| Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL) - House Dust Mite Allergy, Perennial Allergic Rhinitis | Phase 3 | Unknown | Inmunotek S.L. | 400 | 2022-12-01 | 2022-11-18 |
| The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy Nigella Sativa Oil, Allergen Specific Immunotherapy, Standard pharmacotherapy - House Dust Mite Allergy | Not applicable | Unknown | Universitas Airlangga | 40 | 2022-08-01 | 2022-07-08 |
| Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae, Placebo - House Dust Mite Allergy | Phase 3 | Unknown | Probelte Pharma S.L.U. | 350 | 2022-01-17 | 2024-07-18 |
| Airway Immune Response to Allergens (Use Lay Language Here) Segmental allergen challenge - Allergic Asthma, Allergy to Cats | Phase 1 | Unknown | JOSALYN CHO | 12 | 2021-10-28 | 2023-08-31 |
| Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients House Dust Mite Allergen, Allergen-free air - Atopic Dermatitis, House Dust Mite Allergy | Not applicable | Completed | Fraunhofer-Institute of Toxicology and Experimental Medicine | 23 | 2021-09-10 | 2024-10-15 |
| Epigenetic Regulation of Exercise Induced Asthma Exercise challenge in the cold chamber (ECC), mRNA profile, standard diagnostic - Exercise Induced Asthma, House Dust Mite Allergy | Not applicable | Unknown | Johann Wolfgang Goethe University Hospital | 68 | 2021-08-01 | 2022-01-03 |
| The Incidence of Venous Thromboembolism in Atopic Dermatitis Exposure of venous thromboembolism - Venous Thromboembolism, Atopic Dermatitis | Completed | Momentum Data | 754745 | 2021-06-21 | 2024-12-09 | |
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000) - Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis | Phase 3 | Terminated | Inmunotek S.L. | 18 | 2021-04-30 | 2023-12-19 |
| Long-term Effect of a 3-month Supplementation With Holo-BLG on House Dust Mite Induced Allergic Rhinoconjunctivitis Dust Mite Allergy, Allergic Rhinitis | Completed | Ecarf Institute GmbH | 27 | 2021-01-27 | 2022-04-22 | |
| Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients Tregalizumab, Placebo - Allergy to House Dust Mite, Allergic Asthma | Phase 2 | Completed | T-Balance Therapeutics GmbH | 42 | 2020-12-09 | 2022-02-08 |
Showing 20 of 45. Sign in to see all of them.
Hypersensitivity (11) · Rhinitis, Allergic (11) · Asthma (8) · Rhinitis, Allergic, Perennial (4) · Rhinitis (3) · Venom Hypersensitivity (3) · Dermatitis, Atopic (2) · Rhinitis, Allergic, Seasonal (2) · Asthma, Exercise-Induced (1) · Bronchial Hyperreactivity (1) · Conjunctivitis, Allergic (1) · Food Hypersensitivity (1) · Milk Hypersensitivity (1) · Peanut Hypersensitivity (1)
Hypersensitivity, Immediate (45) · Immune System Diseases (45) · Nose Diseases (45) · Otorhinolaryngologic Diseases (45) · Respiratory Tract Diseases (45) · Respiratory Hypersensitivity (44) · Rhinitis (42) · Rhinitis, Allergic, Perennial (41) · Hypersensitivity (34) · Rhinitis, Allergic (34) · Bronchial Diseases (10) · Lung Diseases (9) · Lung Diseases, Obstructive (8) · Infections (3) · Respiratory Tract Infections (3)
Antigens, Dermatophagoides (7) · CYT003-QbG10 (2) · Allergens (1) · Anti-Allergic Agents (1) · Biological Products (1) · Blood Specimen Collection (1) · Bronchial Provocation Tests (1) · Desensitization, Immunologic (1) · Dust (1) · Fish Oils (1) · Fluticasone (1) · Formaldehyde (1) · Histamine (1) · Lacteol (1) · Lactoglobulins (1)
Inmunotek S.L. (5) · Johann Wolfgang Goethe University Hospital (3) · Stallergenes Greer (3) · Allergopharma GmbH & Co. KG (2) · Circassia Limited (2) · Cytos Biotechnology AG (2) · Ecarf Institute GmbH (2) · Fraunhofer-Institute of Toxicology and Experimental Medicine (2) · HAL Allergy (2) · Universitaire Ziekenhuizen KU Leuven (2) · University of North Carolina, Chapel Hill (2) · ALK-Abelló A/S (1) · ASIT Biotech S.A. (1) · Bühlmann Laboratories AG (1) · Hippocreates (1)
Germany (15) · France (7) · Spain (7) · United States (4) · Argentina (2) · Belgium (2) · Poland (2) · United Kingdom (2) · Austria (1) · Bulgaria (1) · Canada (1) · China (1) · Latvia (1) · Lithuania (1) · Portugal (1)
Pascal Demoly, MD (3) · Annemie Narkus, M.D. (2) · Philipp Mueller, MD (2) · Sylvia Becker (2) · Alina Gherasim, MD (1) · Ana Isabel Tabar Purroy, MD. PhD (1) · Ana Isabel Tabar Purroy, MD; PhD (1) · Andrew McGovern, MD (1) · David B Peden, MS/MD (1) · David Peden, MD (1) · Hans Hoogeveen (1)
PMID 20624650, PMID 23331526, PMID 27008542, PMID 29656145, PMID 37418627, PMID 38225952, PMID 39035788
2004 (1), 2008 (1), 2016 (1), 2018 (1), 2023 (1), 2025 (1), U01AI158460 (1)